^
Association details:
| Biomarker: | CDH2 overexpression + KRAS wild-type |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | fexagratinib (ABSK091) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
4489 / 14 - N-Cadherin acts as a predictive biomarker for anti-FGFR therapy in KRAS wild-type NSCLC
Published date:
03/15/2023
Excerpt:
Subsequently, the GDSC repository was used to validated our data in a cohort of lung adenocarcinoma (LUAD) cell lines....we confirm a tendency for increased sensitivity in high N-Cadherin expressing cell lines, but only in KRAS wildtype context.
